Orforglipron Significantly Lowers HbA1c in Two Additional T2D Trials
Topline data from two phase 3 trials evaluating orforglipron, an oral GLP-1 receptor agonist, in patients with type 2 diabetes, were announced.
The ACHIEVE-2 trial compared the efficacy and safety of orforglipron with dapagliflozin in adults with T2D and inadequate glycemic control with metformin.
- Study participants (N=962) had a baseline hemoglobin A1c (HbA1c) of 8.1%.
- Participants were randomly assigned to receive orforglipron (3mg, 12mg, or 36mg) or dapagliflozin (10mg) once daily, alongside background metformin therapy.
The primary endpoint was the change from baseline to week 40 in HbA1c.
No direct quotes available in the text.
Author's summary: Orforglipron lowers HbA1c in T2D trials.